FDA Grants Fast Track Designation to 67Cu-SAR-bisPSMA in mCRPC
The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy after prior treatment, based on SECuRE trial data.
Read More
Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.
Listen
Roundtable Roundup: Bladder Cancer
In separate, live virtual events, David H. Aggen, MD, PhD; and Matthew R. Zibelman, MD, discussed the case of a patient with urothelial carcinoma and potential treatment options.
Juneja Explores AI’s Impact in Early Cancer Detection and Treatment
In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.
Casdatifan Shows Promise in Treating Clear Cell Renal Cell Carcinoma
Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma.
Discussing Lung Cancer NGS Testing and EGFR Treatment Strategies
During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their approaches.
